Amazon study reveals most European employees favour on-the-job skills training or apprenticeships over university degrees for a successful career start
13.6.2024 17:38:00 EEST | Business Wire | Press release
More than half of European workers (54%) believe that on-the-job-skills training or apprenticeships are more valuable for preparing people for work today than traditional university degrees, a new European career insights and workplace trends study commissioned by Amazon has found. In fact, the study found that just under three quarters (73%) of workers feel there needs to be a wider range of apprenticeship or internship opportunities available to young people.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240613014196/en/
The Amazon Future of Work & Career Development European study, conducted by Ipsos, also found that a majority of European employees* (89%) think it’s important to learn a new skill to improve or change their career path, even more so than receiving a promotion (73%). Alongside factors such as pay/salary (94%) and office/worksite location or flexible/hybrid or remote working (93%), 91% of adults say on the job training or career development training is essential or important when looking for a new job or role, and that training programmes offered by a potential employer are more important than company culture (78%). One potential reason is that many workers in the study said it would make them feel motivated (39%), encouraged (32%), valued (31%) or supported (30%) to work for a company that provides access to career development training. Additionally, almost one in five workers in Europe (19%) admit they couldn’t afford to pay for training.
Amazon has long adapted to the ever-changing career and education landscape, investing more than €100 million in training programmes in Europe since it launched its Career Choice programme in the region in 2014. The programme provides 95% of pre-paid tuition, up to €8,000 over four years, for nationally recognised courses from more than 85 schools throughout Europe. It offers various training opportunities in a range of popular, in-demand job fields, from tech and sustainability to business administration and logistics, for Amazon’s hourly and salaried workers across the region.
To mark the ten-year anniversary of Career Choice in Europe, Amazon plans to invest €40 million in 2024 and to add more than 25 new programmes across five countries in Europe this year to support current and future job needs for the thousands of employees who participate in Career Choice. Currently, Amazon employees in Europe have access to over a hundred different programmes to help them maximise their potential within the company or outside of Amazon. Some of the new courses added in 2024 include Cloud Support, Cyber Security, Information Security, Web and Graphic Design, Mechatronics, Procurement Logistics, and Big Data, Virtualisation, and Machine Learning.
Since its launch ten years ago, more than 40,000 Amazon employees across Europe** have participated in the programme. While some employees leave Amazon to pursue other career opportunities with their newly acquired skills and certifications from Career Choice, thousands have stayed and transitioned into new roles. The popularity of the programme continues to increase, with about one in ten of all eligible employees in Europe participating in Career Choice in 2023. Popular areas of study vary from technology and sustainability, to mechanical and industrial systems, transportation and logistics, and administration and business studies.
“I attribute a lot of my growth at Amazon to Career Choice,” said Mo Abdullahi, Senior Operations Manager and Career Choice participant number four in the UK from 2014. “It gave me an opportunity to learn more about the role that I wanted and helped me with obtaining the qualifications that I needed. I'm still super surprised of my journey and growth through Amazon. If I look back ten years ago and starting as a temporary worker, I certainly wouldn't have assumed that I would be at the level I am right now and with the responsibility I have now. It’s been an incredible journey.”
When it comes to jobs in the future, the study shows that training will need to play a key role in alleviating worker concerns, as 32% of European workers are worried they won’t have the training and skills to be relevant in their job in the coming years. In fact, two-thirds of European workers (67%) believe that people in the workforce today will need to continue to retrain and update their skills to continue working in the future. However, only 15% of employees say they have access to training to help them change their career path, and over one in five (22%) employees say they don’t have any access to training with their current employer.
“The latest research and the growth of our Career Choice programme over the past ten years clearly demonstrates the strong desire for workers across the Europe to develop their careers through relevant and accessible skills training programmes,” said Robert Marhan, Global Operations Vice President of People Experience & Technology (PXT). “Amazon is proud to celebrate the tenth anniversary of the Career Choice skills training programme in Europe and to expand the course options available, so that thousands of employees across Europe can advance their skills and take on new career opportunities both at Amazon and beyond.”
The Career Choice programme is currently available to Amazon employees in Australia, Canada, Costa Rica, Czech Republic, France, Germany, Ireland, Italy, Poland, Slovakia, South Africa, Spain, the U.S., and the UK. It has a rigorous selection process for third-party partner educators, choosing partners that are focused on helping employees through their education programmes, assisting them with job placements, and overall offering education that leads to career success.
To learn more about the Career Choice programme, visit Amazon Career Choice https://www.aboutamazon.eu/news/tag/working-at-amazon/career-choice
Sources:
*The research was carried out by Ipsos UK on behalf of Amazon. Ipsos UK interviewed a representative quota sample of 16,482 adults using its online omnibus, and within that a sample of 9,686 employees. Fieldwork was carried out in 8 markets across Europe, including Spain, Germany, UK, France, Italy, Slovakia, Czech Republic, Poland. The sample achieved is representative of the population aged 16-75 in all markets except Czech Republic and Slovakia, where the participants were aged 16-65. Interlocking quotas were set on Age within Gender, and on Region and Working status. The data has been weighted to the known offline population proportions for interlocking cells of gender within age and working status, as well as region and education to reflect the adult population of each market. A country average weight was also applied. Fieldwork was carried out between the 26th April and 27th May 2024. This research was conducted as part of a global study across Australia, Canada, Czech Republic, France, Germany, Italy, Poland, South Africa, Slovakia, Spain, and the UK.
**Amazon Career Choice participation data collected in Europe between 2014-24.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613014196/en/
Contacts
Louise Thach thachl@amazon.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom